JP2017532343A5 - - Google Patents

Download PDF

Info

Publication number
JP2017532343A5
JP2017532343A5 JP2017520447A JP2017520447A JP2017532343A5 JP 2017532343 A5 JP2017532343 A5 JP 2017532343A5 JP 2017520447 A JP2017520447 A JP 2017520447A JP 2017520447 A JP2017520447 A JP 2017520447A JP 2017532343 A5 JP2017532343 A5 JP 2017532343A5
Authority
JP
Japan
Prior art keywords
pharmaceutical preparation
mammal
heart failure
neuregulin
ejection fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017520447A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532343A (ja
Filing date
Publication date
Priority claimed from CN201410550212.7A external-priority patent/CN105561298A/zh
Application filed filed Critical
Publication of JP2017532343A publication Critical patent/JP2017532343A/ja
Publication of JP2017532343A5 publication Critical patent/JP2017532343A5/ja
Pending legal-status Critical Current

Links

JP2017520447A 2014-10-17 2015-10-08 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物 Pending JP2017532343A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201410550212.7A CN105561298A (zh) 2014-10-17 2014-10-17 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
CN201410550212.7 2014-10-17
PCT/CN2015/091459 WO2016058493A1 (zh) 2014-10-17 2015-10-08 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020139931A Division JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Publications (2)

Publication Number Publication Date
JP2017532343A JP2017532343A (ja) 2017-11-02
JP2017532343A5 true JP2017532343A5 (enExample) 2018-10-18

Family

ID=55746124

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017520447A Pending JP2017532343A (ja) 2014-10-17 2015-10-08 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2020139931A Pending JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2022108771A Pending JP2022153417A (ja) 2014-10-17 2022-07-06 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2024135192A Pending JP2024164068A (ja) 2014-10-17 2024-08-14 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2020139931A Pending JP2020193217A (ja) 2014-10-17 2020-08-21 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2022108771A Pending JP2022153417A (ja) 2014-10-17 2022-07-06 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物
JP2024135192A Pending JP2024164068A (ja) 2014-10-17 2024-08-14 駆出率が保たれた心不全を予防し、治療し、又は遅延させるための方法及びニューレグリン組成物

Country Status (10)

Country Link
US (3) US10561709B2 (enExample)
EP (2) EP3207940B1 (enExample)
JP (4) JP2017532343A (enExample)
KR (2) KR102603711B1 (enExample)
CN (3) CN105561298A (enExample)
AU (2) AU2015333335B2 (enExample)
CA (1) CA2963322A1 (enExample)
ES (1) ES2924395T3 (enExample)
RU (1) RU2017116973A (enExample)
WO (1) WO2016058493A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
JP6475623B2 (ja) 2012-10-08 2019-02-27 ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド 糖尿病患者における心不全の治療用組成物
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
JP7575272B2 (ja) * 2018-04-11 2024-10-29 サルブリス バイオセラピューティクス，インコーポレイティド ヒトニューレグリン－１（ｎｒｇ－１）組換え型融合タンパク質組成物及びその使用方法
CN111407881A (zh) * 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CN113289002A (zh) * 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
CN116710139A (zh) * 2020-11-12 2023-09-05 安进股份有限公司 通过施用奥美卡替莫卡必尔治疗心力衰竭的方法
CN117797243A (zh) * 2022-09-30 2024-04-02 上海泽生科技开发股份有限公司 神经调节蛋白及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001489A1 (en) 1987-08-10 1989-02-23 Commonwealth Scientific And Industrial Research Or Control of angiogenesis and compositions and methods therefor
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
IL130827A0 (en) 1997-02-10 2001-01-28 Genentech Inc Heregulin variants
CA2306228A1 (en) 1997-10-14 1999-04-22 Cambridge Neuroscience, Inc. Therapeutic methods comprising use of a neuregulin
US6054261A (en) 1998-05-20 2000-04-25 Q-Pharma, Inc. Coenzyme Q10 compositions for organ protection during perfusion
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) * 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
CN1138785C (zh) 1999-06-04 2004-02-18 周明东 生长因子神经调节蛋白及其类似物的新应用
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
WO2001064877A2 (en) 2000-02-28 2001-09-07 Decode Genetics Ehf Human schizophrenia gene
AU2001274947B2 (en) 2000-05-23 2006-08-17 Acorda Therapeutics, Inc. Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
WO2002024889A2 (en) 2000-09-12 2002-03-28 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Optimized cardiac contraction through differential phosphorylation of myosin
US6482624B2 (en) 2000-11-14 2002-11-19 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
RU2180843C1 (ru) 2001-02-19 2002-03-27 Новокузнецкий государственный институт усовершенствования врачей Способ профилактики повторного инфаркта миокарда
CN1498656A (zh) 2002-11-08 2004-05-26 上海泽生科技开发有限公司 神经调节蛋白用于心肌梗死治疗的方法和组合物
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
US20060275770A1 (en) 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
MXPA05012619A (es) 2003-05-21 2006-02-08 Univ Texas Inhibicion de la proteina cinasa c-mu como un tratamiento para la hipertrofia cardiaca y la falla cardiaca.
CN1715926B (zh) 2004-07-02 2011-08-17 上海泽生科技开发有限公司 神经调节蛋白突变体的应用
US20080213395A1 (en) 2004-10-14 2008-09-04 Adventures Plus Pty Ltd Method for the Treatment of Gastrointestinal and Other Disorders with an Admixture of Vitamins
US20060160062A1 (en) 2005-01-14 2006-07-20 Young Lindon H Perfusion and/or preservation solution for organs
US20070141548A1 (en) 2005-03-11 2007-06-21 Jorg Kohl Organ transplant solutions and method for transplanting organs
CN100361709C (zh) 2005-08-30 2008-01-16 山东省生物药物研究院 一种对生命活性物质有保护作用的糖类组合
CN1768859A (zh) 2005-10-24 2006-05-10 天津大学 基于醛基的微粒表面多重生物功能因子组装方法
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CN101394861A (zh) * 2005-12-30 2009-03-25 上海泽生科技开发有限公司 纽兰格林持续给药能改善心脏功能
BRPI0620819A2 (pt) 2005-12-30 2011-11-22 Zensun Shangai Science & Technology Ltd uso de uma neuregulina (nrg) de liberação prolongada, nrg em uma liberação prolongada de uma dosagem baixa constante, e, composição de liberação prolongada para prevenir, tratar ou retardar uma doença ou distúrbio em um mamìfero
US9580515B2 (en) 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
CN101636656A (zh) 2007-01-25 2010-01-27 霍夫曼-拉罗奇有限公司 Igfbp-7在心力衰竭评估中的用途
CN101310766B (zh) * 2007-05-25 2014-04-16 上海泽生科技开发有限公司 神经调节蛋白的新用途
CN101310779A (zh) 2007-05-25 2008-11-26 上海泽生科技开发有限公司 包含神经调节蛋白的装置及药物制剂
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
DK2320933T3 (en) * 2008-07-17 2018-04-16 Acorda Therapeutics Inc THERAPEUTIC DOSAGE OF A NEUREGULIN OR A SUBSEQUENT THEREOF FOR TREATMENT OR PROPHYLAXY OF HEART FAILURE
EP2808339B1 (en) 2008-11-28 2017-02-15 Zensun (Shanghai) Science & Technology, Co., Ltd. Neuregulin peptides and their use
WO2010060266A1 (en) 2008-11-28 2010-06-03 Zensun (Shanghai) Science & Technology Limited Neuregulin and cardiac stem cells
WO2010142141A1 (en) 2009-06-09 2010-12-16 Zensun (Shanghai) Science & Technology Limited Neuregulin based methods for treating heart failure
CN102470161A (zh) 2009-06-09 2012-05-23 上海泽生科技开发有限公司 神经调节蛋白用于治疗心力衰竭的有效剂量
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
JP5890785B2 (ja) 2010-03-10 2016-03-22 センプラ ファーマシューティカルズ，インコーポレイテッド マクロライド抗生物質の非経口製剤
EP2555788B1 (en) * 2010-03-24 2017-10-11 Massachusetts Institute of Technology NEUREGULIN DIMER FOR AN ErbB/HER RECEPTOR FOR USE IN REDUCING CARDIOTOXICITY.
BR112013001594A2 (pt) 2010-07-22 2016-05-17 Reven Pharmaceuticals Inc métodos de tratamento ou melhoria de doenças e para melhorar o desempenho compreendendo o uso de uma solução dipolo magnético estabilizada
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
JP6475623B2 (ja) 2012-10-08 2019-02-27 ゼンスン（シャンハイ）サイエンス アンド テクノロジー カンパニー リミテッド 糖尿病患者における心不全の治療用組成物
CA2904055A1 (en) * 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
CA2911848A1 (en) 2013-05-22 2014-11-27 Zensun (Shanghai) Science & Technology, Ltd. Extended release of neuregulin for treating heart failure
CN104758300A (zh) 2014-01-02 2015-07-08 上海泽生科技开发有限公司 维生素d及其组合物的抗菌用途
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物

Similar Documents

Publication Publication Date Title
JP2017532343A5 (enExample)
RU2017116973A (ru) Способы применения и композиции нейрегулинов для предотвращения, лечения или замедления сердечной недостаточности с сохраненной фракцией выброса
MX2024010140A (es) Nuevos metodos.
AU2018240515A1 (en) Nucleic acids encoding CRISPR-associated proteins and uses thereof
JP2015517488A5 (enExample)
JP2012041342A5 (enExample)
JP2014051497A5 (enExample)
WO2013173129A3 (en) Treatment of amd using aav sflt-1
MX2023003875A (es) Formulacion de una vacuna peptidica.
MX2017010287A (es) Composiciones farmaceuticas que comprenden n-(3,5-dimetoxifenil)-n '-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il)quinoxalin-6-il]eta no-1,2-diamina.
WO2013103919A3 (en) Compositions and methods for treating metabolic disorders
ES2682670T3 (es) Lisinas de bacteriófagos de Streptococcus para la detección y tratamiento de bacterias gram positivas
JP2015518818A5 (enExample)
JP2020517703A5 (enExample)
EP4616914A3 (en) Polypeptides binding to human complement c5
JP2018519366A5 (enExample)
JP2013503110A5 (enExample)
WO2011112867A8 (en) The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
JP2015510393A5 (enExample)
JP2019533722A5 (enExample)
RU2017113775A (ru) Применение нейрегулина в профилактике, лечении или отсрочке развития желудочковой аритмии и его композиция
WO2017062468A8 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3932418A3 (en) Peptides for use in promoting transport of glucose
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1